SynthesisJournal of medical screening2023
The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.
Synthesis in Journal of medical screening, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of COPD in other long-term conditions: a systematic meta review.BMC pulmonary medicine · 2026Pooled it
- Lung Cancer Survivorship: Challenges and Care Needs.Cancers · 2026Review
- Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription.International journal of radiation oncology, biology, physics · 2026Article
- Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study.Journal of the National Cancer Institute · 2026Article
- Article
- Burden and Impact of Frailty and Comorbidity in Individuals Screened for Lung Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Eligibility for Lung Cancer Screening in Switzerland: A Comparative Analysis of Three Data Sources From Lausanne and the Canton of Vaud.International journal of public health · 2026Article
- Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors.Human vaccines & immunotherapeutics · 2025Article
- A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.Cancers · 2025Review
- Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Targeting the molecular crosstalk between diabetes and lung cancer for therapeutic intervention.Discover oncology · 2025Review
- The impact of comorbidities on the all-cause mortality of surgically treated non-small cell lung cancer patients - visualization with the aid of a comorbidome.BMC surgery · 2025Article
- Assessing the clinical impact of severe lung cancer on non-small cell lung cancer: a single-center retrospective study.Translational lung cancer research · 2025Article
- Do Differences in Comorbidity Explain Sex-based Differences in Lung Cancer Screening Outcomes?Annals of the American Thoracic Society · 2025Article
- Positive Screens Are More Likely in a National Lung Cancer Screening Registry Than the National Lung Screening Trial.Journal of the American College of Radiology : JACR · 2025Article
- The Importance of Comorbidities at Baseline and 5-Year Follow-Up in a Lung Cancer Biomarker Screening Trial.Journal of clinical medicine · 2025Article
- Complications during chest tube drainage for iatrogenic pneumothorax.European clinical respiratory journal · 2025Article
- A clinically applicable model more suitable for predicting malignancy or benignity of pulmonary ground glass nodules in women patients.BMC cancer · 2024Article
- Pathological and imaging features of pulmonary invasive mucinous adenocarcinoma-a retrospective cohort study.Translational lung cancer research · 2024Article
- Bronchiectasis is associated with lower lung function in lung cancer screening participants.European radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveComorbidity is associated with adverse outcomes for all lung cancer patients, but its burden is less understood in the context of screening. This review synthesises the prevalence of comorbidities among lung cancer screening (LCS) candidates and summarises the clinical recommendations for screening comorbid individuals.
methodsWe searched MEDLINE, EMBASE, EBM Reviews, and CINAHL databases from January 1990 to February 2021. We included LCS studies that reported a prevalence of comorbidity, as a prevalence of a particular condition, or as a summary score. We also summarised LCS clinical guidelines that addressed comorbidity or frailty for LCS as a secondary objective for this review. Meta-analysis was used with inverse-variance weights obtained from a random-effects model to estimate the prevalence of selected comorbidities.
resultsWe included 69 studies in the review; seven reported comorbidity summary scores, two reported performance status, 48 reported individual comorbidities, and 12 were clinical guideline papers. The meta-analysis of individual comorbidities resulted in an estimated prevalence of 35.2% for hypertension, 23.5% for history of chronic obstructive pulmonary disease (COPD) (10.7% for severe COPD), 16.6% for ischaemic heart disease (IHD), 13.1% for peripheral vascular disease (PVD), 12.9% for asthma, 12.5% for diabetes, 4.5% for bronchiectasis, 2.2% for stroke, and 0.5% for pulmonary fibrosis.
conclusionsComorbidities were highly prevalent in LCS populations and likely to be more prevalent than in other cancer screening programmes. Further research on the burden of comorbid disease and its impact on screening uptake and outcomes is needed. Identifying individuals with frailty and comorbidities who might not benefit from screening should become a priority in LCS research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.